connect with us
For further information please fill the details below:
Skip to main content


nmims-npat-2019logosLC-MS/MS facility at the SPPSPTMApplications invited for JRF positionAttend Info-session on B.Pharm. + MBA
Prashant Kharkar

Dr. Prashant Suresh Kharkar

Professor and Head, Pharmaceutical Quality Assurance

M. Pharm. Sci., Ph. D. (Tech.)

Areas of Specialisation

Pharmaceutical Chemistry

Official Email Id

Office Phone No.

022-42332000 (Extn- 2028)


15 (Industry – 9 years, Academics - 6 years)

Drug discovery professional with expertise in Medicinal Chemistry and Computer-aided Molecular Design (CAMD) and Molecular Modeling. Managed discovery projects (metabolic disorders, cancer, pain, inflammation) in the lead identification and optimization stages. Managed interactions with team members from other disciplines & delivered all project goals in time. Currently working with Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management as Professor & Head, Pharmaceutical Quality Assurance.

Interest areas

  • Preclinical Development of New Chemical Entities (NCEs) 
  • Design and synthesis of new chemical entities (NCEs) as therapeutic agents 
  • Drug repositioning/repurposing 
  • Design and development of novel fluorescent probes and their biomedical applications 
  • Development of novel excipients and their pharmaceutical and material sciences applications 
  • Process development of Active Pharmaceutical Ingredients (APIs) 
  • Development and validation of Analytical Methods 
  • Impurity synthesis and profiling


  • Publications – 46 (International- 44, National- 02) 
  • Book Chapters- 05 
  • Patents- 03 
  • Presentations- 39 (International- 25, National- 14)
  • Government funded projects – 03
    • Completed
      Design and Development of Novel Inhibitors of Inosine 5’-Monophosphate Dehydrogenase II (IMPDH II) as Anti-inflammatory Agents (DST/SERB) (Sanction Order No. SERB/F/60/2014-15 dated 09.04.2014) (Total Outlay Rs. 26,00,000/-) (May 28, 2014-May 27, 2017)(PI)
    • Targeting Therapy-resistant Cancer Stem Cells (BIPP/BIRAC/DBT) (Total Outlay Rs. 1.5 Cr) (Sanctioned) (Collaborator) (Along with Godavari Biorefineries Ltd., Mumbai) 
    • Discovery of Inhibitors of System Xc¯ Transporter, a Novel Therapeutic Target for Glutamate-Mediated Excitoxicity and Epileptogenesis (DBT/NTF) (Reference No. BT/PR4605/MED/30/719/2012) (Rs. 18.16 lakh) (September 2012-August 31, 2015) (Co-PI)
  • Industry projects - 05
    • Completed (Title of the project, name of industry, amount in Rs.)
      o Scale-up of Lead Anti-Cancer Stem Cell Molecule Intermediate (Godavari Biorefineries Ltd., Mumbai)(Total Outlay Rs. 1 lakh) (January 21, 2018 – March 31, 2018)
      o Evaluation of XARTM for the Treatment of Polycystic Ovarian Syndrome using a Mice as an Animal Model (Epigeneres Pvt. Ltd., Mumbai)(October 2017-December 2017) (Total Outlay Rs. 50,000/-)
      o Comparative Evaluation of Microcrystalline Cellulose obtained from Bagasse (MCC-B) with Pharmaceutical Grade MCC. Consultancy Project sponsored by Godavari Biorefineries Ltd., Mumbai. (Total Outlay Rs. 90,000/-) (February 1 – April 30, 2015) (PI)
    • Ongoing
      o Development of Novel Anti-Cancer Stem Cell (CSC) Therapeutics. Consultant to Godavari Biorefineries Ltd., Mumbai (Total Outlay Rs. 14,00,000/-) (2014-2018).
      o Evaluation of XARTM for Anti-Aging Effects (Epigeneres Pvt. Ltd., Mumbai)(October 2017-December 2017) (Total Outlay Rs. 40,000/-)

Conferences/Workshops/Seminars attended


Academic activities:

o He has guided 30 M. Pharm. students for their research projects.

o He has guided FOUR PhDs successfully and TWO candidates are registered under his supervision.


  • Best Research Output of the Year 2017-18 given by SVKM’s NMIMS (Deemed to be University), Mumbai (August 11, 2018) 
  • Best Major Project Thesis in Quality Assurance (QA) (2017-18) to Ms. Madhushree Phalak, Guide: Dr. Prashant S. Kharkar (August 11, 2018) 
  • DST Foreign Travel Grant for presenting research work at Gordon Research Conference on Computer Aided Drug Design, West Dover, USA. (July 2017) 
  • Best Poster Award at International Conference on Pure and Applied Chemistry (ICPAC)-2016, Mauritius (July 2016) (Poster Presented by Mr. Chetan Shah)
  • Indian National Science Academy (INSA) deputation under International Collaboration and Exchange Programme to University of Mauritius, Mauritius (2016)
  • Best e-Presentation Award at the Virtual Conference on Computational Chemistry (VCCC)-2014 organized by University of Mauritius, Mauritius (August 1-31, 2014)
  • Best Poster Award at International Conference on Pure and Applied Chemistry (ICPAC)-2014, Mauritius (June 2014)
  • 2nd Prize in Oral Presentation at Manshodhan-IV (December 2013)
  • DST Foreign Travel Grant for presenting research work at Gordon Research Conference on Bioorganic Chemistry, Andover, USA. (June 2013)
  • 2nd Prize in Oral Presentation at Manshodhan-III (December 2012)
  • All India Rank 1 at the Graduate Aptitude Test in Engineering (GATE)-1998 examination. Score : 99.96 percentile
  • K. C. Mahindra Talent Scholarship for securing 1st rank in T. Y. and Final Yr. B. Pharm.(1997-98) 
  • National Merit Scholarship for securing 90 % in S. S. C.
  • University Grants Commission – Junior Research Fellowship award (1998)
  • University Grants Commission – Senior Research Fellowship award (2000)
  • Chemical Structure Association (CSA) Trust Grant 2003 (US $ 1000) for presenting poster overseas.
  • Council of Scientific and Industrial Research (CSIR) Foreign Travel Grant for presenting research paper at a Conference in Australia

Professional Memberships:

  • Member, Royal Society of Chemistry (RSC)
  • Association of Pharmaceutical Teachers of India (APTI) – Life Membership (December 2012)
  • American Chemical Society (ACS)
  • Molecular Graphics and Modeling Society (MGMS) (2014-15)

Recent Publications:

  1. Sahu, Niteshkumar U.; Purushothaman, Gayathri; Thiruvenkatam, Vijay; Kharkar, Prashant S. Design, synthesis and biological evaluation of Helicobacter pylori inosine 5′-monophosphate dehydrogenase (HpIMPDH) inhibitors. Drug Develop. Res. 2018 (In Press) [Clarivate Analytics Impact Factor (2017): 2.646]. 
  2. Shah, Chetan P.; Kharkar, Prashant S. Discovery of novel human inosine 5′- monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents. Eur. J. Med. Chem. 2018 (In Press). [Clarivate Analytics Impact Factor (2017): 4.816]. 
  3. Shah, Chetan; Kharkar, Prashant S. Newer human inosine 5′-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents. J. Enz. Inhibit. Med. Chem. 2018, 33, 972-977 [Clarivate Analytics Impact Factor (2016): 4.293]. 
  4. Sahu, Nitesh U.; Singh, V.; Ferraris, D. M.; Rizzi, M.; Kharkar, Prashant S. Hit discovery of Mycobacterium tuberculosis inosine 5′-monophosphate dehydrogenase, GuaB2, inhibitors. Bioorg. Med. Chem. Lett. 2018, 28, 1714-1718 [Clarivate Analytics Impact Factor (2016): 2.454].
  5. Hoonjan, M.; Sachdeva, G.; Chandra, S.; Kharkar, Prashant S.; Sahu, N.; Bhatt, Purvi Investigation of HSA as a biocompatible coating material for arsenic trioxide nanoparticles. Nanoscale 2018, 10, 8031-8041. [Clarivate Analytics Impact Factor (2016): 7.367].
Connect With Us x